Know Cancer

forgot password

A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas

Phase 3
18 Years
79 Years
Open (Enrolling)
Metastatic Pancreatic Cancer

Thank you

Trial Information

A Randomized Phase III Study of Weekly ABI-007 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Adenocarcinoma of the Pancreas

A Phase III, open-label randomized, multicenter trial to compare ABI-007(Albumin-bound
Paclitaxel)in combination with gemcitabine administered weekly to standard treatment
(gemcitabine monotherapy) with respect to overall survival, objective tumor response rate
and PFS in patients diagnosed with metastatic adenocarcinoma of the pancreas.

Inclusion Criteria

Inclusion Criteria

A patient will be eligible for inclusion in this study only if all of the following
criteria are met:

1. Patient has definitive histologically or cytologically confirmed metastatic
adenocarcinoma of the pancreas. The definitive diagnosis of metastatic pancreatic
adenocarcinoma will be made by integrating the histopathological data within the
context of the clinical and radiographic data. Patients with islet cell neoplasms are

2. Initial diagnosis of metastatic disease must have occurred ≤6 weeks prior to
randomization in the study.

3. Patient has one or more metastatic tumors measurable by CT scan (or MRI, if patient
is allergic to CT contrast media).

4. Male or non-pregnant and non-lactating female, and ≥ 18 years of age. If a female
patient is of child-bearing potential, as evidenced by regular menstrual periods, she
must have a negative serum pregnancy test (β-hCG) documented 72 hours prior to the
first administration of study drug.

If sexually active, the patient must agree to use contraception considered
adequate and appropriate by the Investigator during the period of administration of
study drug. In addition, male and female patients must utilize contraception after
the end of treatment as recommended in the product's Summary of Product
Characteristics or Prescribing Information provided in the study manual.

5. Patients must have received no previous radiotherapy, surgery, chemotherapy or
investigational therapy for the treatment of metastatic disease. Prior treatment with
5-FU or gemcitabine administered as a radiation sensitizer in the adjuvant setting is
allowed, provided at least 6 months have elapsed since completion of the last dose
and no lingering toxicities are present. Patients having received cytotoxic doses of
gemcitabine or any other chemotherapy in the adjuvant setting are not eligible for
this study.

6. Patient has adequate biological parameters as demonstrated by the following blood
counts at Baseline (obtained ≤14 days prior to randomization):

Absolute neutrophil count (ANC) ≥ 1.5 × 109/L; Platelet count ≥ 100,000/mm3 (100 ×
109/L); Hemoglobin (Hgb) ≥ 9 g/dL.

7. Patient has the following blood chemistry levels at Baseline (obtained ≤14 days prior
to randomization):

AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver
metastases are clearly present, then ≤ 5 × ULN is allowed Total bilirubin ≤ ULN Serum
creatinine within normal limits or calculated clearance ≥ 60 mL/min/1.73 m2 for
patients with serum creatinine levels above or below the institutional normal value.
If using creatinine clearance, actual body weight should be used for calculating
creatinine clearance (e.g., using the Cockroft-Gault formula). For patients with a
Body Mass Index (BMI) >30 kg/m2, lean body weight should be used instead.

8. Patient has acceptable coagulation studies (obtained ≤14 days prior to randomization)
as demonstrated by prothrombin time (PT) and partial thromboplastin time (PTT) within
normal limits (± 15%). (See also Section 6.2 for Baseline PT/PTT analysis).

9. Patient has no clinically significant abnormalities in urinalysis results (obtained
≤14 days prior to randomization).

10. Patient has a Karnofsky performance status (KPS) ≥ 70. Two observers will be required
to assess KPS. If discrepant, the one with the lowest assessment will be considered

11. Patients should be asymptomatic for jaundice prior to Day 1. Significant or
symptomatic amounts of ascites should be drained prior to Day 1. Pain symptoms should
be stable and should not require modifications in analgesic management prior to Day

12. Patient has been informed about the nature of the study, and has agreed to
participate in the study, and signed the Informed Consent Form (ICF) prior to
participation in any study-related activities.

Exclusion Criteria

A patient will not be eligible for inclusion in this study if any of the following
criteria apply:

1. Patient has known brain metastases, unless previously treated and well-controlled for
at least 3 months (defined as clinically stable, no edema, no steroids and stable in
2 scans at least 4 weeks apart).

2. Patient has only locally advanced disease.

3. Patient has experienced a ≥10% decrease in KPS between Baseline visit and within 72
hours prior to randomization.

4. Patient has a ≥20% decrease in serum albumin level between Baseline visit and within
72 hours prior to randomization.

5. History of malignancy in the last 5 years. Patients with prior history of in situ
cancer or basal or squamous cell skin cancer are eligible. Patients with other
malignancies are eligible if they were cured by surgery alone or surgery plus
radiotherapy and have been continuously disease-free for at least 5 years.

6. Patient uses Coumadin.

7. Patient has active, uncontrolled bacterial, viral, or fungal infection(s) requiring
systemic therapy.

8. Patient has known historical or active infection with HIV, hepatitis B, or hepatitis

9. Patient has undergone major surgery, other than diagnostic surgery (i.e.--surgery
done to obtain a biopsy for diagnosis without removal of an organ), within 4 weeks
prior to Day 1 of treatment in this study.

10. Patient has a history of allergy or hypersensitivity to any of the study drugs or any
of their excipients, or the patient exhibits any of the events outlined in the
Contraindications or Special Warnings and Precautions sections of the product or
comparator SmPC or Prescribing Information.

11. History of connective tissue disorders (e.g., lupus, scleroderma, arteritis nodosa).

12. Patients with a history of interstitial lung disease.

13. History of chronic leukemias (e.g., chronic lymphocytic leukemia).

14. Patients with high cardiovascular risk, including, but not limited to, recent
coronary stenting or myocardial infarction in the past year.

15. History of Peripheral Artery Disease (e.g,. claudication, Leo Buerger's disease).

16. Patient has serious medical risk factors involving any of the major organ systems, or
serious psychiatric disorders, which could compromise the patient's safety or the
study data integrity.

17. Patient is enrolled in any other clinical protocol or investigational trial.

18. Patient is unwilling or unable to comply with study procedures, or is planning to
take vacation for 7 or more consecutive days during the course of the study.

Type of Study:


Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

The primary objective of this study is to evaluate the efficacy of the combination of ABI-007 and Gemcitabine versus Gemcitabine alone in improving overall survival in patients with metastatic adenocarcinoma of the pancreas.

Outcome Time Frame:

EOS and Follow-Up

Safety Issue:


Principal Investigator

Daniel Von Hoff, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Scottsdale Clinical Research Institute


United States: Food and Drug Administration

Study ID:




Start Date:

March 2009

Completion Date:

October 2014

Related Keywords:

  • Metastatic Pancreatic Cancer
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Pancreatic Neoplasms



Roswell Park Cancer Institute Buffalo, New York  14263
Fred Hutchinson Cancer Research Center Seattle, Washington  98109
University of Colorado Cancer Center Denver, Colorado  80262
Huntsman Cancer Institute Salt Lake City, Utah  84112
Medical College of Wisconsin Milwaukee, Wisconsin  53226
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana  70809
Virginia Piper Cancer Institute Minneapolis, Minnesota  55407
Florida Hospital Cancer Institute Orlando, Florida  32804
Rocky Mountain Cancer Center Denver, Colorado  80218
Ocala Oncology Center Ocala, Florida  34474
Georgia Cancer Specialists Decatur, Georgia  30033
Central Maine Medical Center Lewiston, Maine  04240
Pacific Shores Medical Group Long Beach, California  90813
City of Hope Duarte, California  91010
Atlanta Cancer Care Atlanta, Georgia  30342
Genesis Cancer Center Hot Springs, Arkansas  71913
Saint Louis University St. Louis, Missouri  63104
South Carolina Oncology Associates Columbia, South Carolina  29201
SUNY Upstate Medical University Syracuse, New York  13210
Tower Cancer Research Foundation Beverly Hills, California  90211
Lakeland Regional Cancer Center Lakeland, Florida  33805
The Center for Cancer and Hematologic Disease Cherry Hill, New Jersey  08003
Lahey Clinic Burlington, Massachusetts  01805
Northeast Georgia Cancer Care, LLC Athens, Georgia  30607
UCLA Los Angeles, California  90095
University of New Mexico Albuquerque, New Mexico  87131
Virginia Cancer Institute Richmond, Virginia  23230
Illinois Cancer Care Peoria, Illinois  61615
Texas Oncology, PA Dallas, Texas  75246-2006
The Center for Cancer and Blood Disorders Fort Worth, Texas  76104
Utah Cancer Specialists Salt Lake City, Utah  84106
Virginia Commonwealth University Richmond, Virginia  
Center for Cancer & Blood Disorders Bethesda, Maryland  20817
Desert Hematology Oncology Medical Group, Inc. Rancho Mirage, California  92270
Kettering Medical Center Kettering, Ohio  45429
Arizona Cancer Center, University of Arizona Tucson, Arizona  85724-5081
Maine Center for Cancer Medicine Scarborough, Maine  04074
University of Oklahoma Health Science Center Oklahoma City, Oklahoma  73104
Hematology Oncology Clinic Baton Rouge, Louisiana  70808
Swedish Health Services Seattle, Washington  98104
Hutchinson Clinic, PA Hutchinson, Kansas  67502
Tennessee Oncology Nashville, Tennessee  37203
Oncology Hematology Care Cincinnati, Ohio  45242
Chattanooga Oncology Hematology Associates Chattanooga, Tennessee  37404
Cancer Care & Hematology Specialists of Chicagoland Niles, Illinois  60714
Phoebe Putney Cancer Center Albany, Georgia  31701
Piedmont Hematology Oncology Winston-Salem, North Carolina  27103
Arena Oncology Associates, PC Great Neck, New York  11021
Mercy Physicians of Oklahoma Tulsa, Oklahoma  74136
TGen Clinical Research Services at Scottsdale Healthcare Scottsdale, Arizona  85258
Indiana University Simon Cancer Center Indianapolis, Indiana  46202
Signal Point Clinical Research Center, LLC Middletown, Ohio  45042
Evergreen Hematology & Oncology Spokane, Washington  99218
University of Pittsburg Medical Center Pittsburg, Pennsylvania  15213
Piedmont Hospital Research Institute Atlanta, Georgia  30309
Orchard Research Skokie, Illinois  60076
NorthShore University HealthSystem Evanston, Illinois  
New York Oncology Hematology PC Albany, New York  12206
Lake County Oncology and Hematology The Villages, Florida  32159
The University Of Texas Medical School At Houston Houston, Texas  77030
UAB Comprenhensive Cancer Center at University of Alabama Birmingham, Alabama  35294
Clearview Cancer Institute Oncology Specialities, P.C. Huntsville, Alabama  35805
Mayo Clinic-Scottsdale Scottsdale, Arizona  85259
Northern Arizona Hematology and Oncology Associates-AOA Sedona, Arizona  86336
University Cancer Institute, LLC Boynton Beach, Florida  33426
Collaborative Research Group Boynton Beach, Florida  33435
FL Cancer Specialist Ft Myers, Florida  33916
Cancer Care & Hemaotology Specialists of Chicagoland Arlington Heights, Illinois  60005
Owsley Brown Frazier Cancer Center Louisville, Kentucky  40245
Mercy Hospital Portland, ME Portland, Maine  04102
Sidney Kimmel Comphrensive Cancer Center, John Hopkins University Baltimore, Maryland  21231
Cancer Center of Excellence/University of MA Medical School Worcester, Massachusetts  01655
St. Mary's/ Duluth Clinic Duluth, Minnesota  55805
University of Minnesota, Masonic Cancer Center Minneapolis, Minnesota  55455
St. John's Medical Research Institute Springfield, Missouri  65807
Hem Onc Associates-NM Albuquerque, New Mexico  87106
Mid Ohio Oncology/Hematology Inc Columbus, Ohio  43219
Cancer Centers of SW OK Lawton, Oklahoma  73505
Cancer Care Associates- Tulsa Tulsa, Oklahoma  74104
St. Mary Medical Center Hem-Onc Group, PC Langhorne, Pennsylvania  19047
Medical City Dallas-US Oncology Dallas, Texas  75230-2510
Texas Oncology, PA/ Methodist Charlton Cancer Center Dallas, Texas  75237
Texas Oncology Laboratories Fort Worth, Texas  76104
Texas Oncology- Plano East Plano, Texas  75075
Texas Oncology-Round Rock Round Rock, Texas  78681
South Texas Oncology and Hematology, P.A San Antonio, Texas  78229
Fairfax-Northern Virginia Hematology-Oncology, P.C. Fairfax, Virginia  22031
Virginia Cancer Specialist, PC Fairfax, Virginia  22031